ClinicalTrials.gg
WithdrawnNCT05128344Updated Apr 20, 2023

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

A Phase 3 interventional study of AMZ002 injectable solution, 0.5mg/mL and Vigabatrin, oral in Spasms, Infantile, sponsored by Amzell. Withdrawn at 41 sites in 8 countries. Open to participants aged 2 Months to 24 Months. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Amzell · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic decision
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
2 Months to 24 Months
Sex
All
01

Study summary

The main purpose of this study is to evaluate the efficacy of AMZ002 compared to Vigabatrin in participants with newly diagnosed infantile spasms (IS).

02

Conditions studied

  • Spasms, Infantile

Keywords

  • AMZ002
  • Vigabatrin
  • Seizures
  • Electroencephalograms
  • Infantile spasms
  • West syndrome
  • Central Nervous System Diseases
  • Epileptic Syndrome
03

In context

Spasms, Infantile

47 studies on the registry are indexed under Spasms, Infantile; 8 are open to participants now.

Browse Spasms, Infantile studies →

Lead sponsor

Amzell is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has been diagnosed with IS within 6 weeks prior to Screening. Diagnostic criteria include both clinical spasms and an EEG pattern consistent with hypsarrhythmia or significant abnormality compatible with IS
  • Participant has normal renal function as defined by an estimated (eGFR) greater than [>] 60 milliliter/minute (mL/min)/1.73 m\^2, calculated as eGFR = 0.413 × (height [Centimeter (cm)]/serum creatinine [milligrams per deciliter {mg/dL}])
  • Participant's legally authorized representative (that is [i.e.], parent or guardian) must provide written obtained per Institutional Review Board (IRB) policy and requirements, consistent with the International Council for Harmonisation (ICH)
  • Participant's parent/guardian is able to understand and willing to comply with study procedures and restrictions

Exclusion criteria

Exclusion Criteria:

  • Participant has been diagnosed with tuberous sclerosis
  • Participant has acute illness considered by the Investigator within 30 days prior to Screening
  • Participant has a diagnosis of recent systemic fungal infection; history of ocular herpes simplex; history of or current peptic ulcer; uncontrolled hypertension or congestive heart failure; or any other condition that would be significantly impacted by the study drug
  • Participant has a preplanned surgery or procedure(s) that would interfere with the conduct of the study
  • Participant has received any prior treatment for IS
  • Participant has been previously treated with adrenocorticotropic hormone (ACTH), , or Vigabatrin for seizures;
  • Participant has been previously treated with a course of corticosteroids for an indication other than seizures within 30 days prior to Screening
  • Participant has a known or suspected allergy to ACTH or Vigabatrin or any component of AMZ002 or Vigabatrin
  • Participant has used any other drug within 30 days or 5 half-lives prior to the first dose of AMZ002 or Vigabatrin (whichever is longer)
  • Participant' s parent/guardian is unable to provide written and/or to complete the daily diary
  • Participant has any other disease, condition, or therapy that, in the opinion of the Investigator, might compromise safety or compliance, preclude the participant from successfully completing the study, or interfere with the interpretation of the results
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    AMZ002

    Drug: AMZ002 injectable solution, 0.5mg/mL

  • Active comparator
    Vigabatrin

    Drug: Vigabatrin, oral

Interventions

  • DrugAMZ002 injectable solution, 0.5mg/mL

    Injectable solution

  • Oral administration

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with Absence of Clinical Spasms as Assessed by Video Electroencephalogram (EEG) at Day 14

    Time frame: At Day 14

  2. Proportion of Participants with Resolution of Hypsarrhythmia or Significant Abnormality Compatible with Infantile Spasms (IS) as Assessed by Video EEG at Day 14

    Time frame: At Day 14

Secondary outcomes

  1. Time from Treatment Initiation to Absence of Clinical Spasms as Assessed by Parent/Guardian Diary

    Time frame: Baseline up to Day 58

  2. Proportion of Participants with Absence of Clinical Spasms as Assessed by Parent/Guardian Diary at Day 14

    Time frame: At Day 14

  3. Proportion of Participants with Recurrence of Clinical Spasms After Initial Response as Assessed by Video EEG/ by Parent/Guardian Diary

    Time frame: From Day 14 up to Day 58

  4. Time from Initial Response to Recurrence of Clinical Spasms

    Time frame: From Day 14 up to Day 58

07

Study locations

41 sites
  • The Childrens Hospital Colorado
    Aurora, Colorado 80045-7106, United States
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • Advent Health Orlando
    Orlando, Florida 32803, United States
  • Arnold Palmer Hospital For Children
    Orlando, Florida 32806, United States
  • Childrens Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Kentucky Hospital
    Lexington, Kentucky 40536, United States
  • Children's Brain Institute
    Lexington, Massachusetts 02420, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201-2119, United States
  • Staten Island University Hospital, North
    Staten Island, New York 10305, United States
  • Wake Forest Baptist Medical Center - PPDS
    Winston-Salem, North Carolina 27157, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75207, United States
  • Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia
    Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, Argentina
  • Paediatric Hospital Dr. Juan P. Garrahan
    Buenos Aires, Argentina
  • CHU Bordeaux - Hopital des Enfants
    Bordeaux, 33076, France
  • HFME-Hospices Civils de Lyon
    Bron, 69500, France
  • Hopital Roger Salengro - CHU de Lille
    Lille, France
  • Hopital Necker - Enfants Malades
    Paris, France
  • Hopital de Hautepierre
    Strasbourg, France
  • All India Institute of Medical Sciences
    New Delhi, Dehli 110029, India
  • Indira Gandhi Institute of Child Health
    Bangalore, Karnataka 560029, India
  • Amrita Advanced Centre for Epilepsy
    Kochi, Kerala 682041, India
  • Bharati Vidyapeeth Deemed University - Bharati Hospital
    Pune, Maharashtra 411043, India
  • Azienda Ospedaliero Universitaria
    Ancona, Italy
  • Pediatric Hospital G. Salesi
    Ancona, Italy
  • AOU Anna Meyer - Clinica di Neurologia Pediatrica
    Firenze, Italy
  • Istituto Pediatrico Giannina Gaslini
    Genova, Italy
  • Ospedale dei Bambini Vittore Buzzi
    Milano, Italy
  • Universita degli Studi di Napoli Federico II
    Neapel, Italy
  • Ospedale Pediatrico Bambino Gesu
    Roma, Italy
  • Policlinico Universitario A.Gemelli
    Roma, Italy
  • Azienda Ospedaliera Universitaria Integrata
    Verona, Italy
  • Neurociencias Estudios Clinicos S.C.
    Culiacán, Mexico
  • HSRT
    Mexico City, Mexico
  • Tecnologico De Monterrey - Hospital Zambrano Hellion - Instituto de Neurologia y Neurocirugia
    Nuevo León, 66278, Mexico
  • The University Clinical Center
    Gdańsk, Gdansk, Poland
  • Provincial Specialist Children's Hospital st. Ludwika
    Kraków, Krakow, Poland
  • Medical University of Warsaw
    Warsaw, 02-091, Poland
  • Institute of Mother and Child
    Warsaw, Poland
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 8041, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05128344
Lead sponsor
Amzell
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Apr 2023 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 20, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion